Survival after combined modality therapy for pancreatic cancer.
Twenty consecutive patients with unresectable, locally advanced pancreatic cancer were treated with split courses of radiotherapy (RT) and simultaneous multidrug chemotherapy consisting of 5 fluorouracil, continuous infusion, streptozotocin, and cisplatin. A separate, retrospective study identified a group of 28 contemporary patients with less advanced pancreatic cancers, all of which were successfully resected. The survival rate of the two groups were similar over the first 2 years, although it initially favored the unresectable group. This pattern of survival among patients treated with combined modality therapy provides a basis for new studies. At the two clinical extremes, these include treatment of unresectable tumors previously considered ineligible for this treatment and initial treatment before resection of stage I tumors.
Bruckner
H W
HW
Department of Neoplastic Disease, Mount Sinai Medical Center, New York, New York 10029-6574.
Kalnicki
S
S
Dalton
J
J
Snady
H
H
Schwartz
G K
GK
Chesser
M R
MR
Lehrer
D
D
Mandeli
J
J
Harpaz
N
N
Janus
C
C
D000230:Adenocarcinoma / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D010190:Pancreatic Neoplasms / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D013311:Streptozocin / Q000008:administration & dosage; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
D013311:Streptozocin; D002945:Cisplatin; D005472:Fluorouracil